Argos Therapeutics, Inc. (NASDAQ:ARGS) Analytical Analysis

87
Games, whether video or board and tabletop, can strengthen skills that can be applied to real life situations. Strategy, critical thinking and calculation skills can be sharpened and applied to real world situations. Honing these skill sets can be particularly beneficial to Airmen in a variety of career fields. (U.S. Air Force photo by Senior Airman Anthony Sanchelli/Released)

Quarterly Sales and EPS Roundup:

Argos Therapeutics, Inc. (ARGS) reported sales (ttm) of 500000, whereas, 1 number of analysts estimated the mean sale of 0.1 million. The analysts estimated sales for the higher end at 0.1 million and lower end at 0.1 million while the year ago reported sale was 0.1 million.

1 number of analysts have estimated the sales of the company for the quarter ending Mar 30, 2017- Mar 31, 2017, analysts estimated mean sale target of 0.38 million while high and low sale targets are estimated at 0.38 million and 0.38 million respectively.

Argos Therapeutics, Inc. (ARGS) reported earning per shares for the quarter ending Nov 13 BMO at -0.13, whereas, 1 number of analysts estimated the mean EPS at -0.2. The analysts estimated EPS for the higher end at -0.2 and lower end at -0.2 while the year ago reported earnings per share was -0.33.

The company has mean EPS estimate of -1.19 reported by 1 number of analyst for the quarter ending Current Qtr.(Dec2017). The analysts estimated mean EPS at -1.19 while the high and low EPS estimate stand at -1.19 and -1.19 respectively. In contrast to the year ago quarter EPS was at -1.53. EPS long term mean growth rate estimated by 0 analysts is at 40.55%, whereas, the high and low Long term growth rate estimated at 45.07.

Valuation Ratios of Argos Therapeutics, Inc. (ARGS) versus the Industry and Sector:

Let’s have a look at some of the important valuation ratios of the Argos Therapeutics, Inc. (ARGS). These ratios are important while doing valuation of the company or the shares of the company.

Argos Therapeutics, Inc. (ARGS) currently has P/E (Price to Earnings) ratio of 0 while the company’s industry has 30.47 P/E and the sector P/E is 33.54. Similarly, the company’s last 5 years high P/E ratio is 0 and low P/E is 0, whereas, the industry’s and sector’s  high P/E for the past year is 40.55 and 45.07 respectively and low P/E ratio for the last 5 years is 23.57 for the industry and 24.14 for the Sector.

Beta is also an important valuation ratio for analyzing the stock of the company, ARGS has Beta of 1.24 while its industry and Sector’s beta remains at 0.9 and 0.89 respectively.

Price to Sale ratio of the company stands at 24.38 while Price to Book Ratio stands at 0. Its Price to Cash Flow ratio shows the value of 0, whereas, the industry and sector ratio of Price to Cash Flow ticked at 22.35 and 23.4 respectively.

5 Year Growth Rate Analysis:

Growth rates are very important while analyzing the long term growth and valuation of a certain company.

5 year sales growth rate is an important factor for valuation analysis, the 5 year sales growth of the company stands at -34.16 while the industry’s and the sector’s growth for next 5 years ticked at 10.12 and 10.32 respectively. The company’s 5 year Earnings per share growth and Capital Spending growth remains at 0 and 128.88.

Argos Therapeutics, Inc. (ARGS) Trading Statistics:

The company surged 24.27% and closed its last trading session at $0.17. The market capitalization of the company is at $12.67 Million. The stock touched 52-week High of $5.68 on 01/09/17 and 52-week Low of $0.13 on 11/02/17. The stock currently has Weekly Volatility of 21.83% and Monthly Volatility of 10.27%. The Beta for the company stands at 1.24 and its Average True Range (ATR) shows a value of 0.03.

 

SHARE